Trial | NCT02180737  Report issue

Title

Dexmedetomidine for Sedation During Radiological Interventional Procedures
Evaluation of Role of Dexmedetomidine as a Sole Agent in Sedation of Cancer Patients Undergoing Radiological Interventional Procedures

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    40
Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.
Study Started
Jan 31
2014
Primary Completion
Dec 31
2014
Study Completion
Jan 31
2015
Last Update
Apr 19
2016
Estimate

Drug Dexmeditomedine

  • Other names: Dexmedetomidine at 0.6 mcg/kg/hr then 0.2 to 1 mcg/kg/hr.

Dexmeditomedine Experimental

Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.

Criteria 

Inclusion Criteria:

Age from 18-65 years old
ASA physical status of I-II
Expected procedure lasting at least 30 minutes

Exclusion Criteria:

Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block.
An alpha2-agonist or antagonist within 14 days before the scheduled procedure.
patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration.
Patients who are allergic to Dexmedetomidine or alpha 2-agonists.
No Results Posted